Invasive fungal disease in patients treated for newly diagnosed acute leukemia

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 695-699

  Hammond, Sarah P ^a,b,c   Marty, Francisco M ^a,b,c   Bryar, Julie M ^a,d   DeAngelo, Daniel J ^b,c   Baden, Lindsey R ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHEMICALLY INDUCED; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LEUKEMIA; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOSES; NEUTROPENIA; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME; VERY ELDERLY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEUKEMIA; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 77956470833     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21776     Document Type: Article

References (26)

1. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: How do we prevent and treat them? Clin Infect Dis 2010;50:405-415.
2. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
3. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331-340.
4. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 2006;91:1068-1075.
5. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359.
6. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol 2007;25:5471-5489.
7. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003;101:3365-3372.
8. Barnes AJ, Wardley AM, Oppenheim BA, et al. Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis. J Infect 1996;33:43-45.
9. Krcmery V, Jr., Oravcova E, Spanik S, et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: Analysis of aetiology risk factors and outcome. J Antimicrob Chemother 1998;41:373-380.
10. Myoken Y, Kyo T, Kohara T, Fujihara M, Sugata T, Mikami Y. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia. Clin Infect Dis 2003;36:1496-1497.
11. Mann PA, McNicholas PM, Chau AS, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009;53:5026-5034.
12. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557-1559.
13. Ananda-Rajah MR, Grigg A, Slavin MA. Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia 2008;166:83-86.
14. Rieger C, Geiger S, Herold T, Nickenig C, Ostermann H. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2007;26:843-845.
15. Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: An omission in patient counseling and follow-up. J Oncol Pharm Pract 2008;14:189-193.
16. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007;39:425-429.
17. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950-952.
18. Cudillo L, Girmenia C, Santilli S, et al. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis 2005;40:1212-1213.
19. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - Has the principle been proven? N Engl J Med 2007;356:409-411.
20. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
21. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998;92:1556-1564.
22. DeAngelo DJ, Dahlberg S, Silverman LB, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood 2007;110:587.
23. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
24. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
25. Koo S, Bryar JM, Page JH, et al. Diagnostic performance of the (1->3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009;49:1650-1659.
26. Pagano L, Caira M, Picardi M, et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality - SEIFEM-C Report. Clin Infect Dis 2007;44:1524-1525.